Kenya at a glance
- Population
- 57.5 million 2025
- Life expectancy at birth
- 63.8 years, 2024
- People aged 65 and over
- 3.0 % of people, 2025
- Health spending per person
- 85 US$ per person, 2023
- Doctors
- 0.29 per 1,000 people, 2023
Updated
Reviewed by Vidhi Upadhyay
Kenya Liquid Biopsy Market Industry Trends and Forecast to 2034: Segmented by (Biomarker, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$24.8 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $5.9 Mn | — | — |
| 2025 (base) | $7.0 Mn | +$1.1 Mn | — |
| 2026 (forecast) | $8.3 Mn | +$1.3 Mn | +18.3% |
| 2027 (forecast) | $9.8 Mn | +$1.5 Mn | +39.9% |
| 2028 (forecast) | $11.6 Mn | +$1.8 Mn | +65.6% |
| 2029 (forecast) | $13.7 Mn | +$2.1 Mn | +95.9% |
| 2030 (forecast) | $16.2 Mn | +$2.5 Mn | +131.7% |
| 2031 (forecast) | $19.2 Mn | +$3.0 Mn | +174.1% |
| 2032 (forecast) | $22.7 Mn | +$3.5 Mn | +224.3% |
| 2033 (forecast) | $26.8 Mn | +$4.2 Mn | +283.6% |
| 2034 (forecast) | $31.8 Mn | +$4.9 Mn | +353.8% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $7.0 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $31.8 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 18.3% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Biomarker, application and end user (see all) |
| Key players | Guardant Health, Inc., Roche, GRAIL, Natera, Exact Sciences Corporation and 1 more (see all) |
| Regulator in Kenya | PPBSource: Pharmacy and Poisons Board. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Liquid biopsy finds cancer signals such as tumour DNA in a blood sample, to detect cancer, guide treatment and check for relapse.
Key segments of the liquid Biopsy market include biomarker (Circulating Tumor DNA, Circulating Tumor Cells and Exosomes) and application (Treatment Selection, Recurrence Monitoring and Early Detection).
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the liquid Biopsy market. Faster approvals and new combinations are improving survival.
Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the liquid Biopsy market.
High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the liquid Biopsy market, especially in low- and middle-income countries.
The liquid Biopsy market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
The Pharmacy and Poisons Board (PPB) registers medical devices as well as medicines.[1] The Social Health Authority (SHA) replaced the National Health Insurance Fund (NHIF) in October 2024.[2]
[1] Pharmacy and Poisons Board. Checked 14 Nov 2026.
[2] Social Health Authority. Checked 14 Nov 2026.
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how liquid Biopsy products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Kenya.
What doctors and scientists are doing in Liquid Biopsy right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.
From our blog
Kenya
Kenya
Kenya
Kenya
Kenya
Kenya
Pharmaceuticals · Kenya
Public Health · Kenya
Digital Health · Kenya
Healthcare Services · Kenya
Pharmaceuticals · Kenya
Pharmaceuticals · Kenya